NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
0.6153
+0.0648 (11.78%)
Jun 11, 2025, 4:00 PM - Market closed
NextCure Employees
NextCure had 43 employees as of December 31, 2024. The number of employees decreased by 39 or -47.56% compared to the previous year.
Employees
43
Change (1Y)
-39
Growth (1Y)
-47.56%
Revenue / Employee
n/a
Profits / Employee
-$1,151,698
Market Cap
17.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NXTC News
- 13 days ago - NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - GlobeNewsWire
- 5 weeks ago - NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 3 months ago - NextCure Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - GlobeNewsWire
- 6 months ago - NextCure Announces Acceptance of IND Application for LNCB74 - GlobeNewsWire
- 7 months ago - NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 7 months ago - Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - GlobeNewsWire